MM
MCID: MYL069
MIFTS: 85

Myeloma, Multiple (MM)

Categories: Blood diseases, Bone diseases, Cancer diseases, Genetic diseases, Nephrological diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Myeloma, Multiple

MalaCards integrated aliases for Myeloma, Multiple:

Name: Myeloma, Multiple 57 38 40
Multiple Myeloma 57 38 12 76 53 25 59 75 37 29 13 6 43 44 15 73
Plasma Cell Myeloma 12 53 59 55
Medullary Plasmacytoma 25 59 73
Plasma Cell Dyscrasia 53 25 73
Myelomatosis 53 25 59
Multiple Myeloma, Resistance to 57 6
Primary Systemic Amyloidosis 59 73
Primary Amyloidosis 59 73
Kahler's Disease 25 59
Kahler Disease 53 25
Multiple Myeloma, Susceptibility to 57
Immunoglobulin Deposition Disease 73
Systemic Al Amyloidosis 59
Light-Chain Amyloidosis 59
Kahler-Bozzolo Disease 25
Plasma Cell Neoplasm 73
Plasma Cell Myelomas 25
Myeloma - Multiple 53
Al Amyloidosis 59
Mm 75

Characteristics:

Orphanet epidemiological data:

59
primary systemic amyloidosis
Inheritance: Not applicable;
multiple myeloma
Prevalence: 1-9/100000 (United States),1-9/100000 (Worldwide),1-5/10000 (Europe),1-9/100000 (France),1-9/100000 (Europe),1-9/100000 (Australia); Age of onset: Adult;
al amyloidosis
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Adult;

OMIM:

57
Inheritance:
somatic mutation


HPO:

32
myeloma, multiple:
Inheritance somatic mutation autosomal recessive inheritance


Classifications:



Summaries for Myeloma, Multiple

NIH Rare Diseases : 53 Multiple myeloma is a form of cancer that occurs due to abnormal and uncontrolled growth of plasma cells in the bone marrow. Some people with multiple myeloma, especially those with early stages of the condition, have no concerning signs or symptoms. When present, the most common symptom is anemia, which can be associated with fatigue and shortness of breath. Other features of the condition may include multiple infections; abnormal bleeding; bone pain; weak and/or easily broken bones; and numbness and/or weakness of the arms and legs. The exact underlying cause of multiple myeloma is currently unknown. Factors that are associated with an increased risk of developing multiple myeloma include increasing age, male sex, African American race, radiation exposure, a family history of the condition, obesity, and/or a personal history of monoclonal gammopathy of undetermined significance (MGUS). Treatment varies based on many factors, but may include one or more of the following interventions: chemotherapy, corticosteroid medications, targeted therapy, stem cell transplant, biological therapy, radiation therapy, surgery and/or watchful waiting.

MalaCards based summary : Myeloma, Multiple, also known as multiple myeloma, is related to plasma cell leukemia and leukemia, chronic lymphocytic. An important gene associated with Myeloma, Multiple is CCND1 (Cyclin D1), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Cytokine Signaling in Immune system. The drugs Abraxane and Abstral have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are osteopenia and splenomegaly

Disease Ontology : 12 A myeloid neoplasm that is located in the plasma cells in bone marrow.

Genetics Home Reference : 25 Multiple myeloma is a cancer that develops in the bone marrow, the spongy tissue found in the center of most bones. The bone marrow produces red blood cells, which carry oxygen throughout the body; white blood cells, which form the body's defenses (immune system); and platelets, which are necessary for blood clotting.

OMIM : 57 Multiple myeloma is a neoplastic plasma cell disorder characterized by clonal proliferation of malignant plasma cells in the bone marrow microenvironment, monoclonal protein in the blood or urine, and associated organ dysfunction (Palumbo and Anderson, 2011). (254500)

MedlinePlus : 43 Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bones. No one knows the exact causes of multiple myeloma, but it is more common in older people and African Americans. It can run in families. Common symptoms may include Bone pain, often in the back or ribs Broken bones Weakness or fatigue Weight loss Frequent infections and fevers Feeling very thirsty Frequent urination Doctors diagnose multiple myeloma using lab tests, imaging tests, and a bone marrow biopsy. Your treatment depends on how advanced the disease is and whether you have symptoms. If you have no symptoms, you may not need treatment right away. If you have symptoms, you may have chemotherapy, stem cell transplantation, radiation, or targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

UniProtKB/Swiss-Prot : 75 Multiple myeloma: A malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia.

Wikipedia : 76 Multiple myeloma, also known as plasma cell myeloma, is a cancer of plasma cells, a type of white blood... more...

Related Diseases for Myeloma, Multiple

Diseases related to Myeloma, Multiple via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 980)
# Related Disease Score Top Affiliating Genes
1 plasma cell leukemia 33.3 CCND1 FGFR3
2 leukemia, chronic lymphocytic 31.3 BRAF CCND1 HRAS KRAS MIR19A NRAS
3 leukemia, chronic lymphocytic 2 31.3 BRAF HRAS KRAS MIR106B MIR15A MIR181A2
4 myeloid leukemia 31.1 HRAS IDH1 NRAS PTPN11 TP53
5 leukemia, acute myeloid 31.1 HRAS IDH1 IDH2 KRAS MIR181A2 NRAS
6 prostate cancer 31.0 CCND1 CDK4 HRAS KRAS MIR106B MIR15A
7 myelodysplastic syndrome 31.0 HRAS IDH1 IDH2 KRAS NRAS PTPN11
8 lymphoma, non-hodgkin, familial 31.0 TP53 NRAS CCND1 BRAF
9 sarcoma 30.9 BRAF CDK4 HRAS KRAS TP53
10 lung cancer 30.9 BRAF CCND1 CDK4 FGFR3 HRAS KRAS
11 adenocarcinoma 30.7 BRAF CCND1 CDK4 FGFR3 HRAS KRAS
12 adenoma 30.7 BRAF CCND1 KRAS TP53
13 skin melanoma 30.7 TP53 NRAS BRAF
14 thyroid cancer 30.6 BRAF CCND1 HRAS KRAS NRAS TP53
15 melanoma 30.5 BRAF CDK4 MIR15A MIR181A2 MIR19A NRAS
16 suppression of tumorigenicity 12 30.5 BRAF HRAS IDH1 TP53
17 hepatocellular carcinoma 30.5 CCND1 CDK4 HRAS IDH1 IDH2 KRAS
18 lung cancer susceptibility 3 30.4 BRAF CCND1 CDK4 FGFR3 HRAS IDH1
19 noonan syndrome 3 30.3 PTPN11 KRAS HRAS
20 rectal neoplasm 30.3 TP53 KRAS HRAS
21 carcinosarcoma 30.3 TP53 KRAS HRAS
22 thyroid cancer, nonmedullary, 1 30.3 BRAF MIR15A MIR181A2
23 squamous cell carcinoma, head and neck 30.3 BRAF CCND1 CDK4 FGFR3 HRAS IDH2
24 glioma 30.3 BRAF CCND1 CDK4 IDH1 IDH2 MIR15A
25 ovarian cancer 30.2 BRAF CCND1 CDK4 KRAS MIR106B TP53
26 colorectal cancer 30.2 BRAF CCND1 CDK4 FGFR3 HRAS KRAS
27 glioblastoma 30.2 BRAF CCND1 CDK4 HRAS IDH1 IDH2
28 hyperplastic polyposis syndrome 30.2 BRAF KRAS TP53
29 pancreatic cancer 30.2 CCND1 CDK4 HRAS KRAS MIR15A MIR181A2
30 squamous cell carcinoma 30.2 TP53 HRAS FGFR3 CCND1 BRAF
31 pancreas adenocarcinoma 30.2 CCND1 HRAS KRAS TP53
32 gastric adenocarcinoma 30.2 BRAF CCND1 HRAS KRAS NRAS TP53
33 adamantinoma of long bones 30.2 BRAF CCND1 CDK4 KRAS TP53
34 bladder cancer 30.2 CCND1 CDK4 FGFR3 HRAS KRAS TP53
35 gastric cancer 30.2 CCND1 KRAS MIR106B MIR25 MIR93 TP53
36 endometrial cancer 30.2 BRAF CCND1 CDK4 HRAS KRAS TP53
37 transitional cell carcinoma 30.2 BRAF FGFR3 HRAS TP53
38 glioma susceptibility 1 30.1 IDH1 IDH2 TP53
39 colorectal adenoma 30.1 TP53 KRAS HRAS
40 gastrointestinal stromal tumor 30.1 BRAF CCND1 KRAS TP53
41 esophageal cancer 30.1 CCND1 CDK4 HRAS KRAS TP53
42 glioblastoma multiforme 30.1 TP53 IDH1 CDK4 CCND1
43 neuroblastoma 30.1 TP53 PTPN11 NRAS MIR93 FGFR3
44 monoclonal gammopathy of uncertain significance 11.7
45 light chain deposition disease 11.7
46 medial medullary syndrome 11.6
47 plasma cell neoplasm 11.5
48 indolent myeloma 11.5
49 waldenstrom macroglobulinemia 11.4
50 epidermolysis bullosa acquisita 11.4

Graphical network of the top 20 diseases related to Myeloma, Multiple:



Diseases related to Myeloma, Multiple

Symptoms & Phenotypes for Myeloma, Multiple

Symptoms via clinical synopsis from OMIM:

57
Laboratory Abnormalities:
paraproteinemia
high m-component
monoclonal gammopathy
primary immunoglobulin-related amyloidosis (al)

Neoplasia:
multiple myeloma


Clinical features from OMIM:

254500

Human phenotypes related to Myeloma, Multiple:

59 32 (show top 50) (show all 82)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 osteopenia 59 32 hallmark (90%) Very frequent (99-80%) HP:0000938
2 splenomegaly 59 32 very rare (1%) Very rare (<4-1%) HP:0001744
3 nephropathy 59 32 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0000112
4 fatigue 59 32 frequent (33%) Frequent (79-30%),Very frequent (99-80%) HP:0012378
5 generalized muscle weakness 59 32 frequent (33%) Frequent (79-30%) HP:0003324
6 anemia 59 32 frequent (33%) Frequent (79-30%) HP:0001903
7 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
8 pathologic fracture 59 32 hallmark (90%) Very frequent (99-80%) HP:0002756
9 decreased antibody level in blood 59 32 frequent (33%) Frequent (79-30%),Occasional (29-5%) HP:0004313
10 nephrotic syndrome 59 32 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0000100
11 paresthesia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003401
12 elevated serum creatinine 59 32 frequent (33%) Frequent (79-30%) HP:0003259
13 hypercalcemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003072
14 bone pain 59 32 frequent (33%) Frequent (79-30%) HP:0002653
15 abnormality of the bladder 59 32 occasional (7.5%) Occasional (29-5%) HP:0000014
16 acute kidney injury 59 32 frequent (33%) Frequent (79-30%) HP:0001919
17 lymphadenopathy 59 32 very rare (1%) Very rare (<4-1%),Frequent (79-30%) HP:0002716
18 tall stature 59 32 occasional (7.5%) Occasional (29-5%) HP:0000098
19 pleural effusion 59 32 very rare (1%) Very rare (<4-1%),Occasional (29-5%) HP:0002202
20 functional abnormality of the gastrointestinal tract 59 32 occasional (7.5%) Occasional (29-5%) HP:0012719
21 increased iga level 59 32 occasional (7.5%) Occasional (29-5%) HP:0003261
22 vertebral compression fractures 59 32 occasional (7.5%) Occasional (29-5%) HP:0002953
23 spinal cord compression 59 32 occasional (7.5%) Occasional (29-5%) HP:0002176
24 multiple myeloma 59 32 Frequent (79-30%) HP:0006775
25 increased igg level 59 32 frequent (33%) Frequent (79-30%) HP:0003237
26 hyperproteinemia 59 32 frequent (33%) Frequent (79-30%) HP:0002152
27 abnormality of vitamin b12 metabolism 59 32 occasional (7.5%) Occasional (29-5%) HP:0004341
28 osteoarthritis 59 Occasional (29-5%)
29 hypertension 59 Occasional (29-5%)
30 constipation 59 Frequent (79-30%)
31 macroglossia 59 Occasional (29-5%)
32 hepatomegaly 59 Frequent (79-30%)
33 malabsorption 59 Occasional (29-5%)
34 renal insufficiency 59 Frequent (79-30%)
35 proteinuria 59 Frequent (79-30%)
36 arthralgia 59 Frequent (79-30%)
37 hypertrophic cardiomyopathy 59 Very frequent (99-80%)
38 dyspnea 59 Frequent (79-30%)
39 arrhythmia 59 Frequent (79-30%)
40 hepatitis 59 Occasional (29-5%)
41 abnormal blistering of the skin 59 Occasional (29-5%)
42 congestive heart failure 59 Frequent (79-30%)
43 goiter 59 Occasional (29-5%)
44 keratoconjunctivitis sicca 59 Occasional (29-5%)
45 hematuria 59 Occasional (29-5%)
46 xerostomia 59 Occasional (29-5%)
47 purpura 59 Occasional (29-5%)
48 gastrointestinal hemorrhage 59 Occasional (29-5%)
49 papule 59 Occasional (29-5%)
50 skeletal muscle hypertrophy 59 Occasional (29-5%)

GenomeRNAi Phenotypes related to Myeloma, Multiple according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.55 BRAF CDK4 FGFR3 HRAS KRAS
2 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.35 CDK4 FGFR3 HRAS NRAS PTPN11
3 Reduced mammosphere formation GR00396-S 9.23 BRAF CCND1 CDK4 HRAS IDH2 KRAS

MGI Mouse Phenotypes related to Myeloma, Multiple:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.18 BRAF CCND1 CDK4 FGFR3 HRAS KRAS
2 endocrine/exocrine gland MP:0005379 10.11 BRAF CCND1 CDK4 HRAS KRAS LIG4
3 neoplasm MP:0002006 10.11 BRAF CCND1 CDK4 FGFR3 HRAS IDH2
4 craniofacial MP:0005382 10.1 BRAF CCND1 FGFR3 HRAS KRAS NRAS
5 integument MP:0010771 10.09 BRAF CCND1 CDK4 FGFR3 HRAS KRAS
6 normal MP:0002873 9.97 BRAF CCND1 CDK4 FGFR3 HRAS KRAS
7 liver/biliary system MP:0005370 9.95 BRAF CDK4 KRAS LIG4 NRAS PTPN11
8 respiratory system MP:0005388 9.76 BRAF CCND1 FGFR3 HRAS IDH1 KRAS
9 pigmentation MP:0001186 9.73 BRAF CDK4 KRAS NRAS PTPN11 TP53
10 skeleton MP:0005390 9.61 BRAF CCND1 FGFR3 HRAS IDH1 KRAS
11 vision/eye MP:0005391 9.23 BRAF CCND1 CDK4 FGFR3 KRAS NRAS

Drugs & Therapeutics for Myeloma, Multiple

FDA approved drugs:

(show top 50) (show all 211)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Abraxane 18 49 PACLITAXEL Celgene October 2012
2
Abstral 18 FENTANYL (citrate) ProStrakan January 2011
3
Adcetris 18 49 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
4
Afinitor 18 49 EVEROLIMUS Novartis March 2009
5
Alimta 18 49 PEMETREXED (also Pemetrexed Disodium) Eli Lilly February 2004
6
Aloxi 18 49 PALONOSETRON (hydrochloride) MGI Pharma, Helsinn Healthcare August 2003
7
Aredia 18 49 PAMIDRONATE DISODIUM Chiron August 1996
8
Arimidex 18 49 ANASTROZOLE AstraZeneca January 1996
9
Aromasin Tablets 18 49 EXEMESTANE Pharmacia & Upjohn October 21. 1999
10
Arranon 18 49 NELARABINE GlaxoSmithKline October 2005
11
Arzerra 18 49 OFATUMUMAB GlaxoSmithKline October 2009
12
Avastin 18 49 BEVACIZUMAB Genentech July 2009
13
Beleodaq 18 49 BELINOSTAT Spectrum Pharmaceuticals July 2014
14
Bexxar 18 49 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
15
Blincyto 18 49 BLINATUMOMAB Amgen December 2014
16
Bosulif 18 49 BOSUTINIB MONOHYDRATE Pfizer September 2012
17
Bromfenac 18 BROMFENAC SODIUM Duract, Wyeth-Ayerst Laboratories July 1997
18
Busulfex 18 49 BUSULFAN Orphan Medical February 1999
19
CEA-Scan 18 Immunomedics April 1996
20
Cervarix 18 49 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
21
Clolar 18 49 CLOFARABINE Genzyme December, 2004
22
Cometriq 18 49 CABOZANTINIB S-MALATE Exelixis November 2012
23
Cyramza 18 49 RAMUCIRUMAB Eli Lilly April 2014
24
Degarelix 18 49 degarelix Ferring Pharmaceuticals December of 2008
25
Doxil 18 49 DOXORUBICIN HYDROCHLORIDE Alza June 1999
26
Elitek 18 49 RASBURICASE sanofi-aventis October 2009
27
Emend 18 49 APREPITANT FOSAPREPITANT DIMEGLUMINE Merck March 2003
28
Erbitux 18 49 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
29
Erivedge 18 49 VISMODEGIB Genentech January 2012
30
Erwinaze 18 49 asparaginase Erwinia chrysanthemi Eusa Pharma November of 2011
31
Ethyol 18 AMIFOSTINE Alza December 8, 1995
32
Eulexin 18 FLUTAMIDE Schering-Plough June 1996
33
Evista 18 49 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
34
Farydak 18 49 PANOBINOSTAT LACTATE Novartis February 2015
35
Faslodex 18 49 FULVESTRANT AstraZeneca April 2002
36
Folotyn 18 49 PRALATREXATE Allos Therapeutics September 2009
37
Fusilev 18 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
38
Gardasil 18 49 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
39
Gazyva 18 49 OBINUTUZUMAB Genentech October of 2013
40
Gilotrif 18 49 AFATINIB DIMALEATE Boehringer Ingelheim July 2013
41
Gliadel Wafer 18 49 CARMUSTINE Rhone-Poulenc Rorer, Guilford Pharmaceuticals February 1997
42
Halaven 18 49 ERIBULIN MESYLATE Eisai November 2010
43
Herceptin 18 49 TRASTUZUMAB Genentech October 1998
44
Ibrance 18 49 PALBOCICLIB Pfizer February 2015
45
Iclusig 18 49 PONATINIB HYDROCHLORIDE Ariad Pharmaceuticals December 2012
46
Imbruvica 18 49 IBRUTINIB Pharmacyclics November of 2013/February 2014
47
Inlyta 18 49 AXITINIB Pfizer January 2012
48
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
49
Iressa 18 49 GEFITINIB AstraZeneca May 2003
50
Istodax 18 49 ROMIDEPSIN Gloucester Pharmaceuticals November 2009

Drugs for Myeloma, Multiple (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 714)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 179324-69-7 387447 93860
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1177-87-3
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
5
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118072-93-8 68740
6
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
7
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
8
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 148-82-3 4053 460612
9
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
10
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
11
Lenalidomide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 191732-72-6 216326
12
Fludarabine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
13
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
14
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 32326 21704
15
Apixaban Approved Phase 4,Phase 3,Phase 2 503612-47-3 10182969
16
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
17
Daratumumab Approved Phase 4,Phase 2,Phase 3,Phase 1 945721-28-8
18
Mesna Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3375-50-6 598
19
Phentolamine Approved Phase 4 50-60-2 5775
20
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 52-24-4 5453
21 Ixazomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1072833-77-2
22
Ofloxacin Approved Phase 4,Phase 3,Phase 2 82419-36-1 4583
23
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 100986-85-4 149096
24
Liraglutide Approved Phase 4 204656-20-2 44147092
25
Serine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 56-45-1 5951
26
Glycine Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 56-40-6 750
27
Pirarubicin Investigational Phase 4 72496-41-4
28
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 31703
29 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 2629)
# Name Status NCT ID Phase Drugs
1 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
2 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4 zometa
3 A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma Unknown status NCT01868828 Phase 4 PAD;VCD
4 Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma Unknown status NCT02773550 Phase 4 Bortezomib;Melphalan;Prednisone
5 Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma Completed NCT01731886 Phase 4 Lenalidomide;Dexamethasone
6 A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma Completed NCT02268890 Phase 4 Bortezomib
7 A Multiple Myeloma Trial in Patients With Bone Metastases Completed NCT00104104 Phase 4 zoledronic acid
8 Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma Completed NCT00652041 Phase 4 Bortezomib;Thalidomide;Bortezomib
9 Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Patients Completed NCT00622505 Phase 4 zoledronic acid
10 Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability Completed NCT00257114 Phase 4 bortezomib
11 Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
12 REmoval of Free Light Chains. A COmpaRison of Three Different dialyzERs Completed NCT02950389 Phase 4
13 PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
14 Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy Completed NCT00524407 Phase 4 Epoetin alfa
15 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4 Zoledronic acid
16 FREE Study - Fracture Reduction Evaluation Completed NCT00211211 Phase 4
17 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
18 Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Completed NCT00361140 Phase 4 Busulfan;Fludarabine
19 A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Recruiting NCT03416374 Phase 4 Ixazomib;Bortezomib;Carfilzomib;Lenalidomide;Dexamethasone
20 Prolonged Protection From Bone Disease in Multiple Myeloma Recruiting NCT02286830 Phase 4 Zoledronic acid
21 An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma (MM) Previously Receiving a Bortezomib-based Induction Regimen (US MM-6) Recruiting NCT03173092 Phase 4 Ixazomib;Lenalidomide;Dexamethasone
22 PDD vs PAD to Treat Initially Diagnosed MM Recruiting NCT02577783 Phase 4 Chemotherapy with PDD regimen;Chemotherapy with PAD regimen
23 Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse Active, not recruiting NCT01087008 Phase 4 zoledronic acid
24 Modified Bortezomib-based Combination Therapy for Multiple Myeloma Active, not recruiting NCT02559154 Phase 4 Bortezomib;Dexamethasone;Doxorubicin;Cyclophosphamide;Mitoxsnteone;Thalidomide
25 Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Active, not recruiting NCT02958969 Phase 4 Apixaban;Placebo Oral Tablet
26 Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents Enrolling by invitation NCT03619252 Phase 4 Standard Antibacterial Prophylaxis
27 A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent Not yet recruiting NCT03768960 Phase 4 Daratumumab
28 Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients. Not yet recruiting NCT02006225 Phase 4 Plerixafor
29 Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat Not yet recruiting NCT02920190 Phase 4 Liraglutide
30 Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy Terminated NCT01100879 Phase 4 Ferric carboxymaltose
31 A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B Terminated NCT02608060 Phase 4 Epoetin Beta
32 Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma Withdrawn NCT01410929 Phase 4
33 Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. Withdrawn NCT00242528 Phase 4 Zoledronic acid
34 Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma Unknown status NCT00002653 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;prednisone
35 Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma Unknown status NCT00014339 Phase 3 Wobe-Mugos E;melphalan;prednisone
36 CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma Unknown status NCT02362165 Phase 3 Cyclophosphamide;Bortezomib;Dexamethasone;Doxorubicin
37 Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma Unknown status NCT00028886 Phase 3 cyclophosphamide;dexamethasone;doxorubicin hydrochloride;melphalan;thalidomide;vincristine sulfate
38 Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma Unknown status NCT00002599 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;methylprednisolone;prednisone;vincristine sulfate
39 High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy Unknown status NCT00747877 Phase 3 cyclophosphamide;melphalan
40 Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma Unknown status NCT00003603 Phase 3 cyclophosphamide;dexamethasone;idarubicin;lomustine;melphalan;prednisolone
41 MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation Unknown status NCT00256776 Phase 3 Velcade (Bortezomib);Thalidomide;Dexamethasone
42 Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs Unknown status NCT02066454 Phase 3 Apixaban
43 Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple Myeloma Unknown status NCT00998270 Phase 2, Phase 3
44 Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy Unknown status NCT00571168 Phase 3 Emend;Placebo
45 VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM) Unknown status NCT01134484 Phase 3 Velcade;Thalidomide;Dexamethasone
46 Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients Unknown status NCT00872352 Phase 3
47 Comparable Investigation of One Fraction Radiotherapy and Multifraction Radiotherapy in Patients With Multiple Myeloma. Unknown status NCT02024815 Phase 3
48 Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years Unknown status NCT01532856 Phase 3 Thalidomide, Cyclophosphamide, Dexamethasone;Thalidomide, Dexamethasone;Thalidomide, Melphalan, Prednisone
49 Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) Unknown status NCT00910897 Phase 3 Velcade-Dexamethasone;Velcade-Thalidomide-Dexamethasone
50 Hematopoietic Stem Cell Transplantation in Myeloma Unknown status NCT00415987 Phase 2, Phase 3

Search NIH Clinical Center for Myeloma, Multiple

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Myeloma, Multiple cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: multiple myeloma

Genetic Tests for Myeloma, Multiple

Genetic tests related to Myeloma, Multiple:

# Genetic test Affiliating Genes
1 Multiple Myeloma 29 CCND1 LIG4

Anatomical Context for Myeloma, Multiple

MalaCards organs/tissues related to Myeloma, Multiple:

41
Bone, Bone Marrow, T Cells, Breast, B Cells, Lung, Testes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Myeloma, Multiple:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease

Publications for Myeloma, Multiple

Articles related to Myeloma, Multiple:

(show top 50) (show all 6203)
# Title Authors Year
1
Prognostic significance of normalized FDG-PET parameters in patients with multiple myeloma undergoing induction chemotherapy and autologous hematopoietic stem cell transplantation: a retrospective single-center evaluation. ( 30054697 )
2019
2
Anticancer effect of pan-PI3K inhibitor on multiple myeloma cells: Shedding new light on the mechanisms involved in BKM120 resistance. ( 30401630 )
2019
3
Scutellarein selectively targets multiple myeloma cells by increasing mitochondrial superoxide production and activating intrinsic apoptosis pathway. ( 30551468 )
2019
4
All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. ( 30471652 )
2019
5
Role of RACK1 on cell proliferation, adhesion, and bortezomib-induced apoptosis in multiple myeloma. ( 30315883 )
2019
6
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces peripheral blood abnormalities and plasma cell neoplasms resembling multiple myeloma in mice. ( 30343114 )
2019
7
Mechanisms underlying the increased chemosensitivity of bortezomib-resistant multiple myeloma by silencing nuclear transcription factor Snail1. ( 30365089 )
2019
8
The short-term effect of histone deacetylase inhibitors, chidamide and valproic acid, on the NF‑κB pathway in multiple myeloma cells. ( 30387821 )
2019
9
18F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System. ( 30187105 )
2019
10
miR-29b inhibits the progression of multiple myeloma through downregulating FOXP1. ( 30068241 )
2019
11
Alcohol consumption and risk of multiple myeloma in the NIH-AARP Diet and Health Study. ( 29971781 )
2019
12
Bone marrow adiposity and multiple myeloma. ( 29548987 )
2019
13
Dysphagia due to macroglossia in a patient with amyloidosis associated with multiple myeloma: A case report. ( 29889980 )
2018
14
MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling. ( 28905994 )
2018
15
Hepatobiliary and Pancreatic: Pancreatic cancer with elevated serum IgG4 level due to multiple myeloma mimicking localized autoimmune pancreatitis. ( 29761833 )
2018
16
Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma. ( 29978498 )
2018
17
Multiple myeloma causing interstitial pulmonary infiltrates and soft-tissue plasmacytoma. ( 29977785 )
2018
18
Seronegative alveolar echinococcosis in a patient with multiple myeloma. ( 29425710 )
2018
19
Treatment of relapsed multiple myeloma complicated by cardiac extramedullary plasmacytoma with D-PACE chemotherapy. ( 29523615 )
2018
20
Drug response prediction in high-risk multiple myeloma. ( 29122646 )
2018
21
Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center Experience. ( 29158114 )
2018
22
IL17A and IL23R gene polymorphisms affect the clinical features and prognosis of patients with multiple myeloma. ( 28786198 )
2018
23
DANFIN functions as an inhibitor of transcription factor NF-I_B and potentiates the antitumor effect of bortezomib in multiple myeloma. ( 29284118 )
2018
24
IgA kappa light and heavy chain deposition disease in multiple myeloma. ( 29808912 )
2018
25
Membrane translocation of Bruton kinase in multiple myeloma cells is associated with osteoclastogenic phenotype in bone metastatic lesions. ( 29480835 )
2018
26
Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma. ( 29235380 )
2018
27
Systemic mastocytosis with concurrent multiple myeloma. ( 29599147 )
2018
28
Multiple myeloma cells adapted to long-exposure of hypoxia exhibit stem cell characters with TGF-I^/Smad pathway activation. ( 29309790 )
2018
29
Clinicopathological Characteristics of Hyperdiploidy with High-Risk Cytogenetics in Multiple Myeloma. ( 29214761 )
2018
30
Novel YAP1 Activator, Identified by Transcription-Based Functional Screen, Limits Multiple Myeloma Growth. ( 29061667 )
2018
31
High NRF2 expression controls endoplasmic reticulum stress induced apoptosis in multiple myeloma. ( 29031566 )
2018
32
Anti-ZIC4 associated paraneoplastic cerebellar degeneration in a patient with both diffuse large B-cell lymphoma and incidental smoldering multiple myeloma. ( 29249374 )
2018
33
Long Non-Coding RNAs in Multiple Myeloma. ( 29389884 )
2018
34
Immunohistochemical Labeling of Multiple Myeloma Oncogene 1/Interferon Regulatory Factor 4 (MUM1/IRF-4) in Canine Cutaneous Histiocytoma. ( 29444632 )
2018
35
Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. ( 28479151 )
2018
36
TRIM56 Suppresses Multiple Myeloma Progression by Activating TLR3/TRIF Signaling. ( 29214775 )
2018
37
Epigenetic silencing of LPP/miR-28 in multiple myeloma. ( 28775176 )
2018
38
Light Chain Deposition Disease Associated With Multiple Myeloma Developing in Late Pregnancy. ( 29507277 )
2018
39
Interferon I^ is a strong, STAT1-dependent direct inducer of BCL6 expression in multiple myeloma cells. ( 29510136 )
2018
40
Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. ( 29390932 )
2018
41
Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma. ( 28987930 )
2018
42
Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation. ( 29706650 )
2018
43
Comparative analysis of the surgical treatment results for multiple myeloma bone disease of the spine and the long bone/soft tissue. ( 29928372 )
2018
44
Successful Treatment of Recurrent Gastrointestinal Bleeding due to Small Intestine Angiodysplasia and Multiple Myeloma with Thalidomide - Two Birds with One Stone. ( 29911985 )
2018
45
Hypoxia-inducible KDM3A addiction in multiple myeloma. ( 29444873 )
2018
46
Age-related health care disparities in multiple myeloma. ( 28429426 )
2018
47
Late Relapse of Multiple Myeloma with Testicular Plasmacytoma after Autologous Hematopoietic Stem Cell Transplantation: A Case Report and Review of the Literature. ( 29531008 )
2018
48
Multiple Myeloma and Dual-Energy CT: Diagnostic Accuracy of Virtual Noncalcium Technique for Detection of Bone Marrow Infiltration of the Spine and Pelvis. ( 28799843 )
2018
49
Calorimetric markers for monitoring of multiple myeloma and WaldenstrAPm's macroglobulinemia patients. ( 29362827 )
2018
50
IgM- Kappa type multiple myeloma with simultaneous gastro-esophageal involvement simulating linitis plastica. ( 29747781 )
2018

Variations for Myeloma, Multiple

ClinVar genetic disease variations for Myeloma, Multiple:

6 (show top 50) (show all 288)
# Gene Variation Type Significance SNP ID Assembly Location
1 LIG4 NM_002312.3(LIG4): c.8C> T (p.Ala3Val) single nucleotide variant protective rs1805389 GRCh37 Chromosome 13, 108863609: 108863609
2 LIG4 NM_002312.3(LIG4): c.8C> T (p.Ala3Val) single nucleotide variant protective rs1805389 GRCh38 Chromosome 13, 108211261: 108211261
3 LIG4 NM_002312.3(LIG4): c.26C> T (p.Thr9Ile) single nucleotide variant Benign rs1805388 GRCh37 Chromosome 13, 108863591: 108863591
4 LIG4 NM_002312.3(LIG4): c.26C> T (p.Thr9Ile) single nucleotide variant Benign rs1805388 GRCh38 Chromosome 13, 108211243: 108211243
5 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
6 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
7 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
8 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
9 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
10 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh38 Chromosome 17, 7673806: 7673806
11 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
12 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
13 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
14 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
15 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
16 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
17 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
18 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
19 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
20 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
21 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh38 Chromosome 11, 533467: 533467
22 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
23 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
24 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh37 Chromosome 11, 533467: 533467
25 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Likely pathogenic rs121917759 GRCh37 Chromosome 11, 533466: 533466
26 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Likely pathogenic rs121917759 GRCh38 Chromosome 11, 533466: 533466
27 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
28 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
29 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic rs121918464 GRCh37 Chromosome 12, 112888210: 112888210
30 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic rs121918464 GRCh38 Chromosome 12, 112450406: 112450406
31 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
32 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic rs121918465 GRCh38 Chromosome 12, 112450407: 112450407
33 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
34 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic rs121918465 GRCh38 Chromosome 12, 112450407: 112450407
35 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
36 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh38 Chromosome 1, 114716124: 114716124
37 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
38 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh38 Chromosome 1, 114713908: 114713908
39 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
40 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs121434596 GRCh38 Chromosome 1, 114716123: 114716123
41 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
42 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh38 Chromosome 7, 140753336: 140753336
43 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 NCBI36 Chromosome 7, 140099605: 140099605
44 BRAF NM_004333.4(BRAF): c.1397G> T (p.Gly466Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913351 GRCh37 Chromosome 7, 140481411: 140481411
45 BRAF NM_004333.4(BRAF): c.1397G> T (p.Gly466Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913351 GRCh38 Chromosome 7, 140781611: 140781611
46 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh37 Chromosome 7, 140453145: 140453145
47 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh38 Chromosome 7, 140753345: 140753345
48 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
49 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 GRCh38 Chromosome 7, 140781603: 140781603
50 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402

Copy number variations for Myeloma, Multiple from CNVD:

7 (show top 50) (show all 303)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13351 1 1 125000000 Gain Multiple myeloma
2 14061 1 103799708 118390708 Loss Multiple myeloma
3 14338 1 107200000 120600000 Loss and deletion Multiple myeloma
4 14696 1 110000000 184000000 Gain SELL Multiple myeloma
5 16446 1 124300000 247249719 Rearrangement Multiple myeloma
6 17396 1 142600000 155000000 Gain Plasma-cell dyscrasia
7 17400 1 142600000 156500000 Gain and amplification Multiple myeloma
8 17467 1 142902432 245422432 Gain Multiple myeloma
9 20609 1 153300000 154800000 Gain AIM2 Multiple myeloma
10 20611 1 153300000 154800000 Gain EST1B Multiple myeloma
11 20700 1 1536308 6536308 Loss Multiple myeloma
12 20848 1 154800000 157300000 Gain UFC1 Multiple myeloma
13 20849 1 154800000 158800000 Gain CAPON Multiple myeloma
14 20882 1 155000000 156500000 Gain and amplification Multiple myeloma
15 26152 1 197500000 205300000 Gain CHI3L1 Multiple myeloma
16 26153 1 197500000 205300000 Gain PTPN7 Multiple myeloma
17 26162 1 197500000 222100000 Gain GUK1 Multiple myeloma
18 29497 1 23265113 23869113 Loss Multiple myeloma
19 29829 1 236600000 249250621 Gain and amplification Multiple myeloma
20 31636 1 2900000 120700000 Gain CD53 Multiple myeloma
21 31729 1 30200000 32400000 Loss and deletion Multiple myeloma
22 31749 1 30500000 184000000 Gain Multiple myeloma
23 33943 1 50669458 53683458 Loss Multiple myeloma
24 33949 1 50700000 59000000 Loss and deletion Multiple myeloma
25 35189 1 60900000 69500000 Gain NFIA Multiple myeloma
26 36791 1 80821425 83677425 Loss Multiple myeloma
27 36969 1 84171854 96213854 Loss Multiple myeloma
28 37035 1 84700000 88100000 Gain Multiple myeloma
29 37040 1 84700000 94500000 Gain DISC1 Multiple myeloma
30 37519 1 9200000 12700000 Loss and deletion Multiple myeloma
31 37525 10 30762871 30790767 Gain EST Multiple myeloma
32 38898 10 105800000 114900000 Loss and deletion Multiple myeloma
33 40402 10 127500000 135534747 Loss and deletion Multiple myeloma
34 41379 10 17300000 22600000 Gain and amplificati on Multiple myeloma
35 48571 11 100828925 102320925 Loss ANGPTL5 Multiple myeloma
36 48572 11 100828925 102320925 Loss BIRC2 Multiple myeloma
37 48573 11 100828925 102320925 Loss BIRC3 Multiple myeloma
38 48574 11 100828925 102320925 Loss KIAA1377 Multiple myeloma
39 48575 11 100828925 102320925 Loss MMP1 Multiple myeloma
40 48576 11 100828925 102320925 Loss MMP10 Multiple myeloma
41 48577 11 100828925 102320925 Loss MMP12 Multiple myeloma
42 48578 11 100828925 102320925 Loss MMP13 Multiple myeloma
43 48579 11 100828925 102320925 Loss MMP20 Multiple myeloma
44 48580 11 100828925 102320925 Loss MMP27 Multiple myeloma
45 48581 11 100828925 102320925 Loss MMP3 Multiple myeloma
46 48582 11 100828925 102320925 Loss MMP7 Multiple myeloma
47 48583 11 100828925 102320925 Loss MMP8 Multiple myeloma
48 48584 11 100828925 102320925 Loss PORIMIN Multiple myeloma
49 48585 11 100828925 102320925 Loss TRPC6 Multiple myeloma
50 48586 11 100828925 102320925 Loss YAP1 Multiple myeloma

Expression for Myeloma, Multiple

Search GEO for disease gene expression data for Myeloma, Multiple.

Pathways for Myeloma, Multiple

Pathways related to Myeloma, Multiple according to KEGG:

37
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

Pathways related to Myeloma, Multiple according to GeneCards Suite gene sharing:

(show top 50) (show all 114)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.45 BRAF CCND1 FGFR3 HRAS KRAS NRAS
2
Show member pathways
13.14 BRAF FGFR3 HRAS KRAS NRAS TP53
3
Show member pathways
13.14 CCND1 CDK4 HRAS KRAS NRAS TP53
4
Show member pathways
13.07 CCND1 CDK4 FGFR3 HRAS KRAS NRAS
5
Show member pathways
12.94 BRAF CCND1 HRAS KRAS NRAS
6
Show member pathways
12.93 BRAF FGFR3 HRAS KRAS NRAS
7
Show member pathways
12.92 FGFR3 HRAS KRAS NRAS